Identification of cell surface antigens associated with tumor diagnosis and therapy for

A pharmaceutical composition comprising one or more components selected from the group consisting of: (i) a tumor-associated or a portion thereof comprising at least 6 consecutive amino acids of the tumor-associated antigen antigen as defined in (a), (ii) a nucleic acid encoding a tumor associated or part thereof comprising at least 6 consecutive amino acids of the antigen associated with a tumor as defined in (a) antigen, (iii) an antisense nucleic acid specifically hybridizes to a nucleic acid encoding a tumor associated antigen, (iv) a host cell expressing an antigen associated with a tumor, or a portion thereof comprising at least 6 consecutive amino acids of the antigen associated with a tumor such as defined in (a), and (v) isolated complexes between a tumor-associated or a portion thereof comprising at least 6 consecutive amino acids of a tumor associated antigen such antigen c omo defined in (a) and an HLA molecule, wherein the tumor-associated antigen having a sequence which is encoded by a nucleic acid selected from the group consisting of: (a) a nucleic acid comprising the sequence nucleic acid according to SEQ ID NO: 9 in sequence listing, and (b) a nucleic acid having at least 80% nucleotide identity with the nucleic acid of (a).